Trial
NCT04729725
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
—
Condition
Advanced Malignant Solid Neoplasm
Intervention
Anti-TGF-beta Monoclonal Antibody SAR-439459
Why stopped
The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-14